Locus  

Safety evaluation of the antimicrobial peptide bovicin HC5 orally administered to a murine model

Show simple item record

dc.contributor.author Paiva, Aline Dias
dc.contributor.author Fernandes, Kenner Morais
dc.contributor.author Dias, Roberto Sousa
dc.contributor.author Rocha, Alípio dos Santos
dc.contributor.author Oliveira, Leandro Licursi de
dc.contributor.author Neves, Clóvis Andrade
dc.contributor.author Paula, Sérgio Oliveira de
dc.contributor.author Mantovani, Hilário Cuquetto
dc.date.accessioned 2019-03-15T16:28:54Z
dc.date.available 2019-03-15T16:28:54Z
dc.date.issued 2013
dc.identifier.issn 14712180
dc.identifier.uri http://dx.doi.org/10.1186/1471-2180-13-69
dc.identifier.uri http://www.locus.ufv.br/handle/123456789/23977
dc.description.abstract Bovicin HC5 is an antimicrobial peptide that shows a broad spectrum of activity and potential for biotechnological and therapeutic applications. To gain insight about the safety of bovicin HC5 application, the histological and immunostimulatory effects of orally administrated bovicin HC5 to BALB/c mice were evaluated. BALB/c mice were divided into three groups: negative control (NC group); mice given purified bovicin HC5 (Bov group); mice given ovalbumin (positive control, PC group; a murine model of enteropathy). The mice were initially pre-sensitized, and PBS, bovicin HC5 or ovalbumin were administered for 30 days by daily gavages. Histological and morphometric analysis were performed and the relative expression of cytokines was analyzed by real-time RT-PCR. The oral administration of bovicin HC5 to BALB/c mice reduced weight gain and caused alterations in the small intestine, although absorptive changes have not been detected. The number of total goblet cells and the mucopolysaccharides production were not affected by bovicin HC5 administration. A hypertrophy of Paneth cells and an increase in the number of mitotic cells were observed in Bov group, while the number of mast cells remained unaltered. Increased expression of TNF-α, INF-γ and IL-12 was observed in the small intestine upon bovicin HC5 administration. Bovicin HC5 has only minor effects on intestinal permeability and did not elicit an allergenic response upon oral administration to animal models. Considering the low in vivo toxicity of bovicin HC5, it might be a good candidate for enteral applications. en
dc.format pdf pt-BR
dc.language.iso eng pt-BR
dc.publisher BMC Microbiology pt-BR
dc.relation.ispartofseries Volume 13, Number 69, Pages 01- 11, 2013 pt-BR
dc.rights Open Access pt-BR
dc.subject Bacteriocin pt-BR
dc.subject Lantibiotic pt-BR
dc.subject Streptococcus bovis HC5 pt-BR
dc.subject BALB/c mice pt-BR
dc.subject Ovalbumin pt-BR
dc.title Safety evaluation of the antimicrobial peptide bovicin HC5 orally administered to a murine model en
dc.type Artigo pt-BR


Files in this item

This item appears in the following Collection(s)

  • Artigos [268]
    Artigos Técnico-científicos na área de Microbiologia

Show simple item record

Search DSpace


Browse

My Account